Ads
related to: monoclonal antibody treatment prostate cancer results explained- Sign Up for Updates
Sign up to receive the latest data,
case studies, and resources.
- Contact Us
Contact our representatives
for product and reimbursement info.
- Case Studies
Review real case studies
with real patients.
- Find an Imaging Site
Locate the nearest imaging site
or contact customer service.
- Sign Up for Updates
Search results
Results from the WOW.Com Content Network
It binds to the epithelial cell adhesion molecule (EpCAM - CD326), with the intent to trigger antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by Amgen. [1] Adecatumumab has been used in clinical studies of treatment in colorectal, prostate [2] and breast cancers. [3] Phase II results were published ...
Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer. [1] [2]
The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies. The abbreviations in the column Type are as follows: mab: whole monoclonal antibody; Fab: fragment, antigen-binding (one arm)
Antibody-directed enzyme prodrug therapy (ADEPT) involves the application of cancer-associated monoclonal antibodies that are linked to a drug-activating enzyme. Systemic administration of a non-toxic agent results in the antibody's conversion to a toxic drug, resulting in a cytotoxic effect that can be targeted at malignant cells.
Monoclonal antibodies: designed to bind to specific targets on cancer cells, marking cancer cells so that they will be better seen and destroyed by the immune system. Treatment vaccines : also known as therapeutic cancer vaccines, help the immune system learn to recognize and react to mutant proteins specific to the tumor and destroy cancer ...
It is a recombinant humanized monoclonal antibody of the immunoglobulin IgG1 subclass against the interleukin-6 receptor (IL-6R). [18] Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.
Capromab is a mouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked to pendetide , a derivative of DTPA . [ 2 ] Pendetide acts as a chelating agent for the radionuclide indium-111 .
One possible treatment for cancer involves monoclonal antibodies that bind only to cancer-cell-specific antigens and induce an immune response against the target cancer cell. Such mAbs can be modified for delivery of a toxin , radioisotope , cytokine or other active conjugate or to design bispecific antibodies that can bind with their Fab ...
Ads
related to: monoclonal antibody treatment prostate cancer results explained